Chemotherapy for metastatic breast cancer–report of a European expert panel
- 1 December 2002
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 3 (12) , 719-727
- https://doi.org/10.1016/s1470-2045(02)00927-0
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Geriatric oncologyEuropean Journal Of Cancer, 2000
- Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-OverJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of Clinical Oncology, 1998
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1998
- Advanced breast cancer: A randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristineBreast Cancer Research and Treatment, 1996
- Treatment of relapse of breast cancer after adjuvant systemic therapy — Review and guidelines for future researchEuropean Journal Of Cancer, 1994
- Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensBritish Journal of Cancer, 1993